Related Experiment Video
Updated: Mar 11, 2026

A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
Development and Analysis of Novel Therapeutic Targets to Improve Pancreatic β-Cell Function in Type 2 Diabetes
1Department of Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka.
Abstract:
Pancreatic β-cell dysfunction is a major feature of type 2 diabetes. Therefore maintenance of β-cell function is essential to preventing the onset and progression of type 2 diabetes. To elucidate the mechanisms underlying the regulation of insulin secretion and β-cell survival, we particularly focused on the roles of gasotransmitters in pancreatic β-cells. Nitric oxide (NO) and hydrogen sulfide (H2S) are recognized as toxic gases. However, they are also vital physiological and pathophysiological mediators in various cell types. NO, generated from L-arginine by reactions catalyzed by NO synthases, is a well-known neurotransmitter and smooth muscle relaxation factor. In pancreatic β-cells, induction of nitric oxide synthase 2 (NOS2) by inflammatory cytokines generates a large amount of NO, which contributes to the impairment of β-cell function and induction of β-cell apoptosis, which are, in turn, involved in the development of type 1 diabetes. In contrast, a physiological level of NO, generated by constitutive NOS (cNOS), acts as a positive or negative regulator of insulin secretion and β-cell survival, depending on concentration. H2S generated from L-cysteine has been shown to play a role of neuromodulator, and this gas possesses cytoprotective properties. In pancreatic β-cells, H2S functions as a potent suppressor of insulin secretion. Furthermore, chronic exposure to high glucose induces H2S production by increasing the expression of a H2S-producing enzyme, cystathionine γ-lyase (CSE). H2S generated by CSE prevents β-cell apoptosis via an antioxidant mechanism. Here, we describe the current understanding of the function of gasotransmitters in regulating insulin secretion and pancreatic β-cell survival.
Insights
Gasotransmitters like nitric oxide (NO) and hydrogen sulfide (H2S) play dual roles in pancreatic beta-cell function and survival. Understanding these gasotransmitters is key to preventing type 2 diabetes progression.
Area of Science:
- Endocrinology
- Cell Biology
- Biochemistry
Background:
- Pancreatic beta-cell dysfunction is central to type 2 diabetes.
- Gasotransmitters, including nitric oxide (NO) and hydrogen sulfide (H2S), are critical mediators in various cell types.
- Their specific roles in pancreatic beta-cells require elucidation for diabetes management.
Purpose of the Study:
- To investigate the regulatory mechanisms of insulin secretion and beta-cell survival.
- To explore the specific functions of gasotransmitters, NO and H2S, in pancreatic beta-cells.
- To understand how these gases influence diabetes pathogenesis.
Main Methods:
- Review of existing literature on gasotransmitter function in pancreatic beta-cells.
- Analysis of NO production by nitric oxide synthases (NOS) and H2S production by cystathionine gamma-lyase (CSE).
- Examination of the impact of varying concentrations of NO and H2S on insulin secretion and beta-cell apoptosis.
Main Results:
- Nitric oxide (NO) exhibits concentration-dependent effects: high levels from NOS2 impair function and induce apoptosis (linked to type 1 diabetes), while physiological levels from cNOS modulate secretion and survival.
- Hydrogen sulfide (H2S) suppresses insulin secretion but protects beta-cells from apoptosis via antioxidant mechanisms, particularly under high glucose conditions.
- Chronic high glucose increases H2S production by upregulating CSE expression.
Conclusions:
- Gasotransmitters NO and H2S have complex, often opposing, roles in regulating pancreatic beta-cell function and survival.
- Targeting these gasotransmitter pathways may offer novel therapeutic strategies for type 2 diabetes.
- Further research is needed to fully harness the therapeutic potential of NO and H2S in diabetes.
Related Concept Videos
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...

